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Abstract 
Background: Pediatric patients with cerebral palsy (CP) often undergo intramuscular botulinum toxin 
(BoNT-A) injections. These injections can be painful and may require procedural sedation. An ideal 
sedation protocol has yet to be elucidated.  
Objective: To investigate the safety and efficacy of a propofol and ketamine based sedation protocol in 
pediatric patients with cerebral palsy requiring BoNT-A injections.    
Design: This is a retrospective chart review of children with CP undergoing propofol and ketamine based 
sedation for injections with botulinum toxin A. 
Setting: The sedations took place in a procedural sedation suite at a tertiary children’s hospital from Feb 
2013 through Sept 2017. 
Patients: 164 patients with diagnoses of cerebral palsy were included in this study. 
Methods: An initial bolus of 0.5 mg/kg ketamine followed by a 2 mg/kg bolus of propofol was 
administered with supplemental boluses of propofol as needed to achieve deep sedation during the 
intramuscular BoNT-A injections.  
Main Outcome Measurements: Propofol dosages, adverse events, serious adverse events, and sedation 
time parameters were reviewed.  
Results: 345 sedations were successfully performed on 164 patients. The median total dose of propofol was 
4.7 mg/kg (IQR 3.5, 6.3). Adverse events were encountered in 10.1% of procedures including hypoxemia 
responsive to supplemental oxygen (9.6%) and transient apnea (1.4%). The mean procedure time, recovery 
time and total sedation time were 10, 11 and 33 minutes, respectively. With regard to patient variables, 
including age, weight, dose of propofol, sedation time, and Gross Motor Function Classification System 
classification, there was no association with increased incidence of adverse events.  
Conclusion: Our sedation protocol of propofol and ketamine is safe and effective in children with cerebral 
palsy undergoing procedural sedation for intramuscular injections with BoNT-A. The adverse events 
encountered appeared to be related to airway and respiratory complications secondary to musculoskeletal 
deformities, emphasizing the importance of airway monitoring and management in these patients. 
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Introduction 
Cerebral palsy (CP) is a syndrome that involves an early insult to the developing central nervous system 
resulting in a wide variety of clinical presentations including spasticity, contracture, and dyskinesia. It is 
often associated with impairments in learning ability and communication1. Children with CP, due to their 
motor involvement and ongoing spasticity, often require intermittent procedural interventions. 
Intramuscular botulinum toxin A (BoNT-A) injections are commonly indicated in these patients. The 
injections are often painful and frequently require some form of sedation and analgesia to reduce the 
associated pain, anxiety and motor disturbances2-4. 
Children with CP are at an increased risk for anesthetic complications compared to healthy children as they 
are usually at a minimum ASA Class II, referring to mild systemic disease, by the American Society of 
Anesthesiologists5. These children are at increased risk of musculoskeletal deformities, such as contractures 
and kyphoscoliosis, which, over time, lead to restrictive lung disease6-8.  Furthermore, CP also is associated 
with upper airway obstruction, swallowing dysfunction, gastroesophageal reflux, inefficient cough, and 
chronic airway colonization with pathogens6, 9-13. 
Few sedative agents, such as nitrous oxide and benzodiazepines, have been used with variable efficacy in 
this patient population14. Chow and Choong used a ketamine-centered protocol with success in children 
with CP with an adverse event rate of 6.6%15. However, they reported that two hours of monitoring their 
patients after the procedure was required. The ideal sedative protocol in pediatric procedural sedation is one 
that is safe, effective and demonstrates rapid onset and rapid recovery16; this ideal protocol remains elusive 
in this patient population.  
Propofol is a widely used hypnotic agent in pediatric patients for procedural sedation. It is often selected 
due to its rapid onset of action, efficacy in achieving sedation, and rapid emergence from sedation17. Small 
doses of adjunctive ketamine (0.5 mg/kg) have been shown to produce anxiolysis, reduce the total dose of 
propofol required to achieve adequate sedation, and preserve cardiopulmonary function18-23. The use of 
propofol in children with CP for MRI and other procedures has been sparsely documented, and published 
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reports with regards to safety and efficacy of a procedural sedation protocol to facilitate BoNT-A injections 
are lacking24-25.  
 
The aim of this study is to investigate the safety and efficacy of a propofol and ketamine based sedation 
protocol in pediatric patients with cerebral palsy receiving BoNT-A injections.  
 
Methods 
This retrospective chart review was approved by the Indiana University institutional review board. Children 
with CP who underwent procedural sedation with propofol and ketamine for BoNT-A injections to treat 
spasticity between February 2013 and September 2017 were included in the analysis. All patients with 
cerebral palsy had a formal primary diagnosis made by their neurologist and this information was provided 
on the request form by the physician making the referral for BoNT-A. Exclusion criteria included patients 
who were admitted to the hospital at the time of their scheduled study for reasons other than BoNT-A 
injections and patients who were on digoxin or B-blockers. Patient demographics, incidence of adverse 
events and serious adverse events, sedative drug dosages, and procedure, sedation, recovery and discharge 
times were collected. Patients were classified according to the Gross Motor Function Classification System 
(GMFCS), which is a standardized five level classification system (I to V) to classify the gross motor 
function of children with cerebral palsy26. 
 
Our institution has an intensivist-based procedural sedation program that adheres to policies and guidelines 
based on recommendations by the Joint Commission and the American Academy of Pediatrics27-28. Oral 
and enteral intake were withheld for at least 6 hours prior to the onset of the procedure. Patients are 
prescreened via telephone interview by a sedation nurse with a parent/guardian present during the interview 
and by reviewing the chart filled out by the primary physician.  
 
Our sedation team used a standard approach for sedation with propofol and ketamine. An initial bolus of 
0.5 mg/kg of ketamine was administered intravenously followed by a 2 mg/kg bolus of intravenous 
propofol. If unwanted movement occurred, additional boluses of 0.5-1 mg/kg of propofol were given to 
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achieve the desirable level of sedation. The sedation level of the children was measured by the sedation 
team using the Ramsay sedation scale every 5 minutes. The Ramsay scale assigns a score of 1– 6 based on 
the clinical assessment of the level of sedation as follows: (1) anxious, agitated, restless; (2) awake, but 
cooperative, tranquil, oriented and (3) responds to verbal commands only. Scores 4 to 6 were used for 
sleeping patients and are graded according to the response to loud noises or glabellar taps as follows: (4) 
brisk response; (5) sluggish response and (6) no response29. Score 4 and above were accepted as deep 
sedation. A standardized dose of 12 international units/kg, up to a maximum dose of 400 IU, of BotNT-A 
was ordered by the physician in charge of administering the BoNT-A using electronic medical record order 
sets. The exact administered dosage is carefully determined by the physician and can be affected by level of 
spasticity and number of the injected muscles. 
 
Standardized monitoring, in accordance with the AAP 2016 guidelines, is used at our institution for 
procedural sedation, which includes, at a minimum, baseline vitals (including temperature), continuous 
SaO2, heart rate and ventilation monitoring, and automatic blood pressure checks every 5 minutes
28. 
Adverse events were defined as development of transient hypoxemia (oxygen saturation of less than 90% 
for 30 seconds), hypotension (drop in systolic blood pressure [SBP] below expected age appropriate normal 
range or dropping by 20% from starting SBP), transient apnea, nausea and vomiting. Serious adverse 
events such as endotracheal intubation, respiratory or cardiac arrest, failure to complete the procedure, and 
transfer to higher level care were also recorded. Procedure time (PT) was defined as the time between the 
first dose of propofol until the procedure was completed. Recovery time (RT) was defined as the interval 
between the end of the procedure until the patient’s level of consciousness returned to Ramsay level 2. 
Total time was defined as the time recorded by the nurse assisting with the sedation from the first dose until 
the patient was ready for discharge.  
 
Statistical analysis: 
Overall cohort demographics, incidence of adverse events, and sedation time parameters are presented as 
median (IQR) for continuous variables, and frequencies (percent) for categorical variables. Age, weight, 
GMFCS score, ketamine dose, propofol dose, and sedation time parameters were compared for each of the 
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aforementioned adverse events versus those without the events using Wilcoxon rank-sum tests or Fisher's 
exact test as appropriate.  
 
Results 
A total of 345 sedation encounters in 164 patients were performed successfully using propofol and 
ketamine according to our standardized protocol. During the study period, all sedation encounters were 
successfully completed. Patient demographics are shown in Table 1. Most patients (97.6%) were of ASA II 
category. Out of 164 patients, 138 patients (84.1%) were GMFCS III and higher. The median total dose of 
propofol for each procedure was 4.7 mg/kg (IRQ 3.5,6.3). The number of sedations per patient during the 
study period are shown in figure 1. Thirty-five patient encounters (10.1%) out of 345 experienced adverse 
events, of which 33 had hypoxemia (9.6%), 5 (1.4%) had transient apnea, and 3 (0.9%) had both. All 
episodes of hypoxemia and apnea were transient and resolved with only supplemental oxygen via nasal 
cannula. There were no serious adverse events (Table 2). Average procedure time, recovery time and total 
time were 11, 10 and 33 minutes, respectively (Table 3). Patient age, patient weight, dose of propofol, 
procedure time, recovery time, and total nurse time did not vary significantly between the patient groups 
with and without adverse events (Tables 4 and 5). Additionally, incidence of adverse events and 
hypoxemia were not significantly different between the GMFCS classes.  
 
Discussion 
Pediatric patients undergoing procedural sedation require an effective sedation protocol with agents that 
have a rapid onset, a rapid recovery, and a favorable side effect profile. Children with cerebral palsy 
requiring BoNT-A injections present unique challenges due to their developmental abnormalities and the 
pain and distress that can be associated with these procedures30. Our study showed that a propofol and 
ketamine based sedation protocol is both safe and effective when conducted in an appropriate setting with 
providers highly trained in pediatric airway and cardiorespiratory monitoring. We demonstrated that 100% 
of our patients were successfully sedated using our protocol with a mean procedure time of 11 minutes, a 
mean recovery time of 10 minutes, and a mean total time of 33 minutes. In terms of safety, the overall 
incidence of adverse events was 10.1% in our patient population, of which hypoxemia responsive to 
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supplemental oxygen via nasal cannula was the vast majority (9.6%), while transient apnea occurred in 
1.4%. We also found that GMFCS classification had no significant impact on adverse events in these 
patients.  
 
Several studies have demonstrated the benefits of BoNT-A injections in patients with CP as well as its 
functional outcomes31-32. However, little work has been done in regard to regimens to alleviate the pain and 
distress that result from these procedures. Zeir et al compared inhaled nitrous oxide to enteral midazolam 
and demonstrated suboptimal efficacy of both regimens in providing analgesia and desired level of sedation 
to pediatric patients undergoing BoNT-A injections33. 
 
At our institution, we use an adjunctive dose of ketamine prior to propofol administration. This approach in 
anxiolysis prior to sedation has been widely studied and the effects of ketamine are well known throughout 
pediatric patient sub-populations18-20. Ketamine has also been shown to reduce the dose of propofol 
required for sedation, while providing cardiovascular stability and preserving a patient maintained airway 
21-23. Propofol has been studied and shown to be safe and effective in pediatric patients undergoing a variety 
of procedures, like transesophageal echocardiography and magnetic resonance imaging, in both inpatient 
and outpatient settings34-36. More importantly, combining propofol and ketamine has been evaluated in 
large case studies in patients with a variety of primary diagnoses, which include hematologic, oncologic, 
infectious, neurologic and many other diagnoses21, 37. This combination of agents has been studied in the 
emergency department, radiological imaging units and ICU settings and has been found to be safe and 
effective when administered by skilled personnel, while also resulting in a more rapid recovery, shorter stay 
and smoother anesthetic emergence21, 37-40. 
 
Since several of these procedures are often performed in a day, and because patients are routinely 
discharged directly home after the intervention, it is important to have a regimen that allows for rapid onset 
of induction and rapid recovery from sedation. We attribute the speed of recovery and discharge in our 
study to the pharmacologic properties of propofol, specifically its rapid redistribution and clearance from 
circulation41-43. These properties make propofol an ideal agent to be used in the outpatient setting if used by 
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qualified physicians trained in sedation and advanced airway management44-45. The Chow and Choong 
study proposing the use of ketamine and midazolam, and later on ketamine alone, to provide sedation in 
pediatric patients with CP undergoing BoNT-A injections found that those patients required monitoring for 
two hours post-procedure15. This is much longer than the mean total procedure time and mean recovery 
time in our study. We believe that this is likely due to the relatively longer half-life of ketamine compared 
to propofol, particularly when higher doses of ketamine are used. The shorter recovery time using our 
propofol and ketamine based protocol ultimately improved patient throughput and the overall work flow of 
the sedation team.  
 
In terms of safety and adverse events, the overall incidence of adverse events and incidence of hypoxemia 
were 10.1% and 9.6% respectively. This is higher that the incidence of adverse events of 5% reported by 
the Pediatric Sedation Research Consortium data using propofol for sedation in the general pediatric 
population17. In that study, and others, propofol has been shown to be associated with airway obstruction, 
desaturation, and coughing and increased secretions among other adverse events17, 46. However, children 
with CP are at increased risk of desaturation due to higher rates of restrictive lung diseases, muscle 
contractures, increased salivation and higher incidence of gastroesophageal reflux6-13. In our patients, there 
was no difference in adverse events between any of the GMFCS classification groups. This could be due to 
the fact that all sedations were conducted in a consistent location with a dedicated sedation team. This is an 
important finding as it highlights the role of having a skilled sedation staff who were aware of potential 
sedation-related adverse events and having the appropriate equipment readily available in providing equally 
safe and effective procedural sedation to a spectrum of children with CP with different GMFCS 
classifications. In comparing our study to the recent Chow and Choong study, the adverse event rate 
reported for their study was 6.6% in a patient population where only 40.2% of patients were classified as a 
GMFCS of 3 or greater; adverse events reported included rash, nausea and vomiting, tremors, headache, 
and nightmares. We hypothesize that the difference in types of adverse events experienced between our 
study and theirs is mainly due to the pharmacologic agent used while the incidence of adverse events is 
possibly related to a patient population with a higher disease severity based on GMFCS classification. No 
serious adverse events were encountered in our study population.  
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 Our study has a few limitations. It is retrospective in nature and was conducted at a single center with a 
relatively small number of patients. Additionally, our sedations were performed by a pediatric intensivist-
based sedation team, which may limit the generalizability of these findings to other health care providers 
and settings when performing procedural sedation. However, due to the standardized protocol used, and the 
similar safety profile among all children with CP with different complexity levels, it can be argued that our 
protocol can be utilized by other teams with different backgrounds as long as team providers are adequately 
trained in pediatric airway and cardiorespiratory monitoring and management. We are able to report that, 
based on our study, our protocol using propofol and ketamine is quite safe and highly efficacious in 
sedating pediatric patients with cerebral palsy regardless of the severity of their underlying CP. 
 
Conclusion  
In summary, we conclude that a propofol and ketamine based sedation protocol is both a safe and an 
effective method to provide deep sedation for pediatric patients with cerebral palsy undergoing 
intramuscular BoNT-A injections. Furthermore, we believe that this protocol could be utilized to provide 
sedation for other non-invasive and minimally invasive procedures in children with cerebral palsy. Given 
the higher incidence of adverse events in this particular patient population, these patients require vigilant 
monitoring by providers adequately trained in pediatric airway and cardiorespiratory monitoring.  
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Tables 
Table 1: Demographic characteristics of children with cerebral palsy receiving sedation with 
propofol and ketamine for botulinum toxin A injections. 
 
Variable 
 
 
Number of patients = 164 
Age in years 9 (4, 11) 
Weight in kg 26 (20.4, 36.6) 
Sex, female 62 (37.8%) 
ASA classification 
 I 
 II 
 III 
 
1 (0.6%) 
160 (97.6%) 
3 (1.8%) 
GMFCS classification 
I 
II 
III 
IV 
V 
 
5 (3.1%) 
21 (12.8%) 
50 (30.5%) 
55 (33.5%) 
33 (20.1%) 
Number of encounters 1 (1, 3) 
Data presented as median (25th, 75th interquartile range) or number (%) 
ASA=American Society of Anesthesiologists 
GMFCS= Gross Motor Function Classification System 
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Table 2: Incidence of adverse events for all procedures 
Adverse events 
Frequency  
N=345 
Hypotension 0 (0%) 
Hypoxemia 33 (9.6%) 
Apnea 5 (1.4%) 
Nausea and Vomiting 0 (0%) 
All Adverse events  35 (10.1%) 
Serious Adverse Events 0 (0%) 
Data presented as number (%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Table 3: Sedation time parameters . 
Variable  Time (in minutes) 
Procedure Time 11 (9, 14) 
Recovery Time 10 (6, 17) 
Total Sedation Time 33 (27, 40) 
Data presented as median (25th, 75th interquartile range). Data 
presented as median (25th, 75th interquartile range).  
Procedure time was defined as interval from first dose of 
propofol to completion of injections 
Recovery time was defined as the interval from procedure end 
time to consciousness at Ramsay level 
Total time was the sum of both procedure time and recovery 
time. 
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Table 4: Demographics and sedation time parameters for patients with and without hypoxemia   
Variable Hypoxemia 
(N=33) 
No Hypoxemia 
(N=312) 
p-value 
Age in years 5.1 (3.6, 6.3) 5.8 (3.9, 9.4) 0.12 
Weight in kg 19.2 (15.8, 22.8) 20.5 (16.2, 27.9) 0.33 
Dose of Propofol (mg/kg) 5.0 (3.7, 7.0) 4.7 (3.5, 6.1) 0.17 
GMFCS classification 
I 
II 
III 
IV 
V 
 
  3 (18.8%) 
5 (8.3%) 
8 (8.6%) 
8 (6.9%) 
  9 (15.0%) 
 
13 (81.3%) 
55 (91.7%) 
85 (91.4%) 
108 (93.1%) 
51 (85.0%) 
0.33 
Procedure Time 13 (10, 16) 11 (9, 14) 0.06 
Recovery Time 13 (7, 20) 10 (6, 15) 0.09 
Sedation Total Time 36 (32, 41) 33 (26, 40) 0.07 
Data presented as median (25th, 75th interquartile range) 
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Table 5: Demographics and sedation time parameters for patients with and without any 
complication. 
 
Variable Complication During 
Sedation 
(N=35) 
No Complication 
During Sedation 
(N=310) 
p-value 
Age in years 5.0 (3.6, 6.3) 5.9 (3.9, 9.4) 0.09 
Weight in kg 18.7 (15.6, 22.8) 20.6 (16.3, 28.0) 0.2 
Dose of Propofol (mg/kg) 5.1 (3.7, 7.0) 4.6 (3.5, 6.1) 0.09 
GMFCS classification 
I 
II 
III 
IV 
V 
 
  3 (18.8%) 
  6 (10.0%) 
9 (9.7%) 
8 (6.9%) 
  9 (15.0%) 
 
13 (81.3%) 
54 (90.0%) 
84 (90.3%) 
108 (93.1%) 
51 (85.0%) 
0.37 
Procedure Time 13 (10, 16) 11 (9, 14) 0.07 
Recovery Time 13 (7, 20) 10 (6, 15) 0.05 
Sedation Total Time 36 (32, 42) 33 (26, 40) 0.06 
Data presented as median (25th, 75th interquartile range) 
 
Figure 1: Number of sedations received during the study period for patients with CP undergoing 
injections with BoNT-A.  
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